EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel COS/H2S-Donor Hybridized sGC Stimulator for Alleviating Isoproterenol-Induced Myocardial Fibrosis

Yi Yang, Jiafei Wu, Gongyun He, Siqi Yao, Li-Yuan Wei, Quan Wang, Wei Dai, Han Yuan, Jianwen Chen, Xiaoying Wang, Lei Guo iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yi Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Hydrogen Sulfide, Soluble Guanylyl Cyclase, Myocardium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial fibrosis contributes to heart failure (HF) progression, which is associated with impaired nitric oxide (NO)–soluble guanylyl cyclase (sGC)–cyclic guanosine monophosphate (cGMP) signaling. Hydrogen sulfide (H2S), a cardioprotective gasotransmitter, is reduced in patients with HF. Therapeutic options targeting both sGC activation and H2S enhancement remain limited. We have developed a novel carbonyl sulfide (COS)/H2S-donor hybrid sGC stimulator, COS-A, which exhibits a well-characterized H2S-releasing property. Compound COS-A outperformed vericiguat in sGC activation in vitro and reduced fibrosis in transforming growth factor-beta 1 (TGF-β1)-treated cardiac fibroblasts by increasing cGMP and H2S levels. In isoproterenol (ISO)-induced HF mice, COS-A improved cardiac function comparably to vericiguat. Histological findings revealed its antifibrotic effects through sGC activation and elevation of H2S. Our findings indicate that this COS/H2S-donor hybridized sGC stimulator holds therapeutic promise for HF treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydrogen SulfideSoluble Guanylyl CyclaseMyocardiumAnimalsIsoproterenolFibrosisMiceMaleMice, Inbred C57BLDrug DiscoveryHumansCyclic GMPFibroblasts

Substanzen

IsoproterenolHydrogen SulfideSoluble Guanylyl CyclaseCyclic GMP

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
  • Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Sun Yat-sen University Nanchang Research Institute, Nanchang 330096, China.

ORCID-Profile: Lei Guo

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Yang, Y., Wu, J., He, G., Yao, S., Wei, L. Y., Wang, Q., Dai, W., Yuan, H., Chen, J., Wang, X., & Guo, L. (2025). Discovery of a Novel COS/H2S-Donor Hybridized sGC Stimulator for Alleviating Isoproterenol-Induced Myocardial Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02191

Vancouver

Yang Y, Wu J, He G, Yao S, Wei LY, Wang Q, et al. Discovery of a Novel COS/H2S-Donor Hybridized sGC Stimulator for Alleviating Isoproterenol-Induced Myocardial Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02191

BibTeX
@article{Yang2025,
  author = {Yang, Yi and Wu, Jiafei and He, Gongyun and Yao, Siqi and Wei, Li-Yuan and Wang, Quan and Dai, Wei and Yuan, Han and Chen, Jianwen and Wang, Xiaoying and Guo, Lei},
  title = {Discovery of a Novel COS/H2S-Donor Hybridized sGC Stimulator for Alleviating Isoproterenol-Induced Myocardial Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02191}
}
Kostenlos starten →